Atlantic Therapeutics develops professional and consumer medical devices, related software, apps and connected health technologies to treat all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor. All Atlantic Therapeutics products are approved under the European Medical Devices Directive 93/42/EEC Atlantic Therapeutics Group Ltd, has recently successfully completed a €15 million growth capital financing, enabling the company to move forward with next phase of growth and treat millions of people across the globe who suffer from bladder weakness, clinically known as stress urinary incontinence. The funds come from a combination of venture capital investment from Seroba Life Sciences and Earlybird Venture Capital, as well as Bio-medical Research Group Ltd (previous owner) which retains a minority shareholding. The capital enables Atlantic Therapeutics to accelerate growth from INNOVO® technology platform via market and geographic expansion and new product development.